Diabetes Drugs: Onglyza, Januvia, Tradjenta, or Nesina are linked to pancreatic, bladder, kidney, and liver cancer.. and now; heart failure. STOP THE MADNESS!


DPP-4 inhibitors like Onglyza, Januvia, Tradjenta, and Nesina  need to be “readdressed” by the FDA as they are proven to be associated with an increased death rate.

DPP-4 inhibitors are prescribed for type 2 diabetes; they were very quickly studied, quickly obtained  FDA approval, and were quickly distributed via prescription to millions of people.

After the fact Onglyza, Tradjenta, Januvia, and Nesina have been linked to diseases like pancreatic cancer, bladder cancer, liver cancer, and kidney cancer.…People are dying from using these medications and the FDA doesn’t even know why they are killing people..  Imagine that.


ENOUGH!   I can’t take this anymore and you shouldn’t either.  We are being prescribed toxic medications that have been improperly tested ….and these prescription drugs are literally killing us.

Over 65% of the US adult population has metabolic issues.


If you have some of the following medical conditions:  hypertension, high cholesterol, high triglycerides, high glucose, non alcohol fatty liver disease, PCOS, pre diabetes, type 2 diabetes, a history of gestational diabetes, are overweight/obese, suffer from GERD and sleep apnea, Alzheimer’s disease, or have had breast, colon, skin, pancreas, ovary, uterine, prostate, or testicular cancer….consider telling your MD you are going to change your lifestyle to The Metabolism Miracle lifestyle.

Get current weight, body measurements,  blood pressure, metabolic panel, and lipid profile done and have these measures repeated after 8 weeks of living The Metabolism Miracle plan.

In an 8 week time span,  you  will have your medications (types or dosages) decreased or eliminated,  your  lab work and blood pressure will be close to or in your normal range,  your weight/body fat/inches will be significantly decreased,  and you will be energetic, clear thinking, focused, and feeling younger and healthier than ever.  You will not need yet another prescription added to your over-full medicine cabinet.


“NO THANKS,” I don’t want to add more potentially toxic medication until I try 8 weeks on The Metabolism Miracle plan….. The Metabolism Miracle program is the best prescription you can take to get and stay healthy…without negative side effects”.

YOU have control over your body and what goes into it.  Take control of your health now.


Following is an article about a class of diabetes medications called DPP-4 inhibitors.  Remember Paula Dean was the spokesperson for Januvia?   Well, Januvia is a DPP-4 inhibitor.

At the end of this article, I will give you a link to the other article I wrote less than 3 weeks ago when this class of medications was cited for major cancer risk.


New Heart Concerns for Existing Class of Type 2 Medications

Monday, April 27, 2015 by Samuel Grossman, Pharm.D. CDE for DiabetesCare.net

Read more: http://www.diabetescare.net/authors/samuel-grossman/new-heart-concerns-for-existing-class-of-type-2-medications?utm_source=DC.net+-+Providers+Newsletter&utm_campaign=ddbee63af5-DC_net_Provider_Newsletter_April_28_2015&utm_medium=email&utm_term=0_4acaa22c03-ddbee63af5-393542347#ixzz3YdUabx00

On April14, the Food & Drug Administration (FDA) panel reviewed the cardiovascular profile of Onglyza by  AstraZeneca, approved in 2009, and Nesina by Takeda, approved in 2013. Both medications are members of a class known as DPP-4 inhibitors that includes  Januvia, and Tradjenta.

The panel has recommended that Onglyza’s label should include new information about the risk of heart failure. A review of data from the clinical trial SAVOR for patients on Onglyza revealed:

  • An increased risk for hospitalization due to heart failure

A review of data for Nesina by the FDA panel did reveal that the number of hospitalizations in patients on Nesina increased due to heart failure; however, the increase in hospitalizations was not statistically significant.

Drug experts believe the FDA will view the risk as a drug class effect and will apply changes to all approved drugs in the DPP-4 inhibitors class. The FDA is expected to follow the advice of its advisory panel–although it is not obliged to do so.

The question is would this recommendation by the FDA panel affect prescribing habits for providers? As a clinician, I believe that the finding by the FDA panel puts providers on an increased alert. If the patient develops heart failure and is being hospitalized, is it a progression of underlying cardiovascular disease or the negligence of the provider who has prescribed a DPP-4 inhibitor?

Although some believe that the new recommendation by the FDA panel will not change the marketing of DPP-4 inhibitors such as Onglyza and Nesina, I beg to differ. If the FDA decides to add this risk-of-heart-failure caution to the package insert, prescribing habits may change. The concern about the risk of worsening cardiac disease or even hospitalization due to heart failure will force providers to reevaluate the risk vs. benefit of DPP-4 inhibitors. No provider wants to be blamed for exacerbating a risk for hospital admission due to heart failure. I believe that if the FDA adapts the recommendation by the FDA advisory panel, it will also bring concerns to patients who are currently on Onglyza or Nesina and have had heart failure.

The possibility remains that many patients will ask their providers to change their medication regimen. Providers will have to reconsider their approach to diabetes therapy based on their experience for their patient population who are currently on DPP-4 inhibitors such as Onglyza and Nesina without any evidence of worsening of heart failure or any hospitalizations due to heart failure.

When DPP-4 inhibitors are not an option for some patients, there are other medication choices to take their place. I believe that providers can prescribe other classes of drugs including GLP-1 agonists or SGLT-2 inhibitors, if they want to diverse patients’ medication regimens.  At this point, it remains to be seen how the public and healthcare professionals will react to the ruling by the FDA panel and the subsequent decision by the FDA, but stay tuned for future news.



Dig Diane Kress’ work?  Here are links to her books and support site!

 The Metabolism Miracle:   http://www.amazon.com/The-Metabolism-Miracle-Control-Permanently/dp/0738213861/ref=tmm_pap_title_0?ie=UTF8&qid=1411319710&sr=8-1

The Metabolism Miracle Cookbook:   http://www.amazon.com/The-Metabolism-Miracle-Cookbook-Delicious/dp/0738214256/ref=pd_sim_b_1?ie=UTF8&refRID=0DC5FY8CN1D1YH85YNM

The Metabolism Miracle Update:  (Brand new!)http://www.amazon.com/Metabolism-Miracle-Update-Revisions-Diabetes-ebook/dp/B00N4IQUF4/ref=sr_1_1?ie=UTF8&qid=1411319947&sr=8-1&keywords=metabolism+miracle+update

The Diabetes Miracle: http://www.amazon.com/The-Diabetes-Miracle-Prevent-Permanently/dp/0738216011/ref=pd_sim_b_2?ie=UTF8&refRID=03YM32PQDQ2W877F1JTM

The Interactive Support Group for Followers of The Metabolism Miracle and The Diabetes Miracle:  http://www.Miracle-Ville.com

***Follow Diane Kress on:  Twitter, Facebook, Google +, Pinterest, LinkedIn, and http://www.dianekress.wordpress.com.



About Diane Kress

Author of The New York Times Bestseller; The Metabolism Miracle, The Metabolism Miracle Cookbook, and The Diabetes Miracle. and The Metabolism Miracle, Revised Edition. Owner, developer, and administrator of The Metabolism Miracle's support site: www.Miracle-Ville.com. Registered Dietitian, Certified Diabetes Educator, www.themetabolismmiracle.com www.thediabetesmiracle.com www.miracle-ville.com Email: dietquestions@ymail.com
This entry was posted in ADA, AMA, AND, breast cancer, Diane Kress, Diet, DPP-4 inhibitors, Everydayhealth.com, excess insulin, insulin resistance, Januvia, LADA, low carb, Met B, Metabolic syndrome, Metabolism B, Miracle-Ville.com, monitoring blood glucose, Nesina, obesity, Onglyza, overweight, PCOS, pre diabetes, prediabetes, prevent breast cancer, The Diabetes Miracle, The Metabolism Miracle, The Metabolism Miracle Cookbook, The Metabolism Miracle Update, Tradjenta, type 1.5 diabetes, type 2 diabetes, Uncategorized, weigh in and tagged , , , , , , , , . Bookmark the permalink.

One Response to Diabetes Drugs: Onglyza, Januvia, Tradjenta, or Nesina are linked to pancreatic, bladder, kidney, and liver cancer.. and now; heart failure. STOP THE MADNESS!

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s